Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.

被引：11

作者：

Dodick D.W. ^{[1
]}

Lipton R.B. ^{[1
]}

Ferrari M.D. ^{[1
]}

Goadsby P.J. ^{[1
]}

McCrory D. ^{[1
]}

Cutrer F.M. ^{[1
]}

Williams P. ^{[1
]}

机构：

[1] Department of Neurology, Mayo Clinic Scottsdale, 85259, AZ

来源：

Current Pain and Headache Reports | 2004年 / 8卷 / 6期

关键词：

Migraine; Analytic Hierarchy Process; Sumatriptan; Zolmitriptan; Rizatriptan;

D O I：

10.1007/s11916-004-0064-2

中图分类号：

学科分类号：

摘要：

Seven oral triptans, which differ on a range of attributes important for treatment selection, are now available for treating migraine. US neurologists were surveyed to assess the relative importance of treatment attributes, prespecified by clinical relevance and availability of controlled study data, for selecting among oral triptans. Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials.

引用

页码：435 / 442

页数：7

共 66 条

[41]

Isselhardt BJ(undefined)undefined undefined undefined undefined-undefined

[42]

Cappuccio JD(undefined)undefined undefined undefined undefined-undefined

[43]

Deng H(undefined)undefined undefined undefined undefined-undefined

[44]

Yeh C-H(undefined)undefined undefined undefined undefined-undefined

[45]

Willis RJ(undefined)undefined undefined undefined undefined-undefined

[46]

Roon KI(undefined)undefined undefined undefined undefined-undefined

[47]

Lipton R(undefined)undefined undefined undefined undefined-undefined

[48]

Goadsby PJ(undefined)undefined undefined undefined undefined-undefined

[49]

Ferrari M(undefined)undefined undefined undefined undefined-undefined

[50]

Brodie MJ(undefined)undefined undefined undefined undefined-undefined

← 1 2 3 4 5 6 7 →